Chronic heart failure

被引:0
作者
Elaine Winkel
Maria Rosa Costanzo
机构
[1] Rush-Presbyterian-St. Luke’s Medical Center,Heart Failure and Cardiac Transplant Program
关键词
Heart Failure; Digoxin; Left Ventricular Ejection Fraction; Chronic Heart Failure; Carvedilol;
D O I
10.1007/s11936-999-0039-z
中图分类号
学科分类号
摘要
Physicians must aggressively treat heart failure in the early stages to prevent disease progression and improve survival. Early treatment implies early diagnosis of left ventricular (LV) dysfunction, before the onset of symptoms. Patients with risk factors for the development of heart failure, especially coronary disease or hypertension, should undergo echocardiography to evaluate LV function. Patients with LV systolic dysfunction should be further evaluated to determine the type of cardiac dysfunction, uncover correctable etiologic factors, determine prognosis, and guide treatment.Angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic blocking drugs improve survival and are integral to the treatment plan. Physicians should prescribe an ACE inhibitor as initial therapy for all patients with LV systolic dysfunction unless there are specific contraindications. The combination of hydralazine and isosorbide dinitrate is an acceptable alternative therapy for patients who cannot take ACE inhibitors.Diuretics should be used if there are signs or symptoms of volume overload.Beta-adrenergic blocking drugs should be added to therapy in stable patients with mild to moderate heart failure after optimal treatment with ACE inhibitors, diuretics, or other vasodilators.Digoxin should be used routinely in patients with severe heart failure and should be added to therapy in patients with mild to moderate heart failure who remain symptomatic despite optimal doses of ACE inhibitors and diuretics.Spironolactone should be added, but electrolytes should be closely monitored.Warfarin anticoagulation should be considered in patients with a left ventricular ejection fraction (LVEF) of 35% or less.Until survival data exist, angiotensin receptor blockers (ARBs) should not be used as initial therapy or as sole therapy but can be used for ACE-intolerant patients or can be added to standard heart failure therapy.Outpatient use of intravenous inotropic therapy should be avoided.Patients with severe heart failure should have peak oxygen consumption measured to quantify functional impairment, determine prognosis, and identify the need for advanced heart failure therapy.Patients who remain symptomatic while receiving optimal standard therapy should be referred early to a specialized heart failure center.
引用
收藏
页码:231 / 241
页数:10
相关论文
共 45 条
  • [1] Garg R(1995)Guidelines for the evaluation and management of heart failure Circulation 92 2764-2784
  • [2] Yusef S(1999)Consensus recommendations for the management of chronic heart failure Am J Cardiol 83 1A-38A
  • [3] Alderman EL(1995)Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA 273 1450-1456
  • [4] Heidenreich PA(1998)Results from late-breaking clinical trials sessions at ACC 98 J Am Coll Cardiol 32 1-7
  • [5] Lee TT(1997)Effect of beta blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials J Am Coll Cardiol 30 27-34
  • [6] Massie BM(1999)The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial Lancet 353 9-13
  • [7] Packer M(1999)Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 2001-2007
  • [8] Gheorghiade M(1995)Design of the Beta- Blocker Survival Trial (BEST) Am J Cardiol 75 1220-1223
  • [9] Young JB(1997)The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med 336 525-533
  • [10] Uretsky BF(1993)Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors: RADIANCE study N Engl J Med 329 1-7